Influx Healthtech Ltd
Incorporated in September 2020, Influx Healthtech Limited is a healthcare-focused company specialising in contract manufacturing.[1]
- Market Cap ₹ 673 Cr.
- Current Price ₹ 291
- High / Low ₹ 315 / 141
- Stock P/E 32.8
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2026 | |
|---|---|
| 147 | |
| 117 | |
| Operating Profit | 30 |
| OPM % | 20% |
| 1 | |
| Interest | 0 |
| Depreciation | 4 |
| Profit before tax | 27 |
| Tax % | 25% |
| 21 | |
| EPS in Rs | 8.87 |
| Dividend Payout % | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 72% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2026 | |
|---|---|
| Equity Capital | |
| Reserves | |
| Total Liabilities | |
| CWIP | |
| Investments | |
| Total Assets |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2026 | |
|---|---|
| 4 | |
| -25 | |
| 45 | |
| Net Cash Flow | 23 |
| Free Cash Flow | -21 |
| CFO/OP | 41% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2026 | |
|---|---|
| Debtor Days | |
| Inventory Days | |
| Days Payable | |
| Cash Conversion Cycle | |
| Working Capital Days | |
| ROCE % |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Installed Capacity - Cosmetics & Ayurvedic kg per day |
|
|||
| Installed Capacity - Nutraceuticals kg per day |
||||
| Installed Capacity - Pet Supplements & Homecare kg per day |
||||
| Number of Clients count |
||||
| Number of Products (SKUs) count |
||||
| Top 10 Client Revenue Concentration % |
||||
| Capacity Utilization - Nutraceuticals % |
||||
| Number of Export Countries count |
||||
| Number of Manufacturing Units count |
||||
Extracted by Screener AI
Documents
Announcements
-
Reply to Clarification- Financial results
3 July 2026 - Audited FY26 results filed; consolidated format clarified for newly incorporated subsidiary Olahey Wellness.
-
Clarification - Financial Results
24 June 2026 - Exchange has sought clarification from Influx Healthtech Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (LODR) Regulations, 2015. On …
-
Disclosure under SEBI Takeover Regulations
5 June 2026 - Promoter group held 1,70,23,464 shares as of March 31, 2026, with no new encumbrance.
-
Analysts/Institutional Investor Meet/Con. Call Updates
26 May 2026 - FY26 earnings call transcript: revenue Rs146 crore, EBITDA Rs29.9 crore, PAT Rs20.5 crore; 75,000 sq ft facility by Aug 2026.
-
Analysts/Institutional Investor Meet/Con. Call Updates
22 May 2026 - May 22, 2026 investor conference call recording shared; transcript will follow later.
Annual reports
Concalls
-
May 2026Transcript PPT REC
-
Nov 2025Transcript PPT REC
-
Aug 2025TranscriptAI SummaryPPT
Business Profile[1]
The company operates as a Contract Development and Manufacturing Organization (CDMO) catering to B2B clients in nutraceuticals, cosmetics, ayurvedic/herbal products, veterinary feed supplements, and homecare products.
Its core competency is offering end-to-end manufacturing services, including product formulation, development, regulatory support, and commercialization.